Lenalidomide represents a novel effective treatment for multiple myeloma (MM) patients at relapse (Dimopoulos et al, 2009) as well as at the onset (Palumbo et al, 2012). Some poor cytogenetic prognostic factors, particularly alterations of 17p13, seem to maintain their adverse impact in the course of lenalidomide treatment (Reece et al, 2009).
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma
BERNASCONI, PAOLO;CAZZOLA, MARIO;
2013-01-01
Abstract
Lenalidomide represents a novel effective treatment for multiple myeloma (MM) patients at relapse (Dimopoulos et al, 2009) as well as at the onset (Palumbo et al, 2012). Some poor cytogenetic prognostic factors, particularly alterations of 17p13, seem to maintain their adverse impact in the course of lenalidomide treatment (Reece et al, 2009).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
